Jinoos Yazdany

List of Publications by Year in descending order

175 papers	9,610 citations	81900 39 h-index	45317 90 g-index
180 all docs	180 docs citations	180 times ranked	10835 citing authors

#	Article	IF	Citations
1	Response to: â€˜Correspondence on â€˜Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registryâ€™ by Arnaud and Devilliers. Annals of the Rheumatic Diseases, 2023, 82, e114-e114.	0.9	2
2	Response to: â€˜Correspondence on â€˜Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registryâ€™â€™ by Mulhearnet al. Annals of the Rheumatic Diseases, 2023, 82, e116-e116.	0.9	87
3	Response to: â€˜Correspondence on â€˜Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registryâ€™â€™ by Rosenbaumet al. Annals of the Rheumatic Diseases, 2023, 82, e139-e139.	0.9	2
4	Response to: Correspondence on â€œAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registryâ€•by Sparkset al. Annals of the Rheumatic Diseases, 2023, 82, e158-e158.	0.9	3
5	Response to: Correspondence on â€œAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritisâ€•by van Vollenhovenet al. Annals of the Rheumatic Diseases, 2023, 82, e178-e178.	0.9	7
6	Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases. European Journal of Rheumatology, 2023, 9, 185-190.	0.6	2
7	Development of a Natural Language Processing System for Extracting Rheumatoid Arthritis Outcomes From Clinical Notes Using the National Rheumatology Informatics System for Effectiveness Registry. Arthritis Care and Research, 2023, 75, 608-615.	3.4	10
8	Race, Ethnicity, and Disparities in the Risk of <scp>Endâ€Organ</scp> Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. Arthritis Care and Research, 2023, 75, 34-43.	3.4	13
9	Does Higher Quality of Care in Systemic Lupus Erythematosus Improve Quality of Life?. Arthritis Care and Research, 2023, 75, 1198-1205.	3.4	3
10	Significant Gains in Rheumatoid Arthritis Quality Measures Among RISE Registry Practices. Arthritis Care and Research, 2022, 74, 219-228.	3.4	14
11	Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: â€˜Correspondence on â€˜Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryâ€™ by Gianfrancescoet al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseasesâ€™ by Giolloet al. Annals of the Rheumatic Diseases, 2022, 81, e223-e223.	0.9	5
12	Treatment of Sarcoidosis in <scp>US</scp> Rheumatology Practices: Data From the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (<scp>RISE</scp>) Registry. Arthritis Care and Research, 2022, 74, 371-376.	3.4	8
13	Quality of Care for Patients With Systemic Lupus Erythematosus: Data From the American College of Rheumatology <scp>RISE</scp> Registry. Arthritis Care and Research, 2022, 74, 179-186.	3.4	5
14	Physical Inactivity and Incident Depression in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care and Research, 2022, 74, 1098-1104.	3.4	5
15	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. Journal of Rheumatology, 2022, 49, 110-114.	2.0	9
16	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. Journal of Rheumatology, 2022, 49, 320-329.	2.0	24
17	Rapid Adoption of Telemedicine in Rheumatology Care During the <scp>COVID</scp>â€19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. ACR Open Rheumatology, 2022, 4, 128-133.	2.1	6
18	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. Nature Reviews Rheumatology, 2022, 18, 9-21.	8.0	21

#	Article	IF	Citations
19	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	3.9	30
20	The impact of COVID-19 on rheumatology trainingâ€"results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.7	7
21	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nature Reviews Rheumatology, 2022, 18, 191-204.	8.0	105
22	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
23	Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus. ACR Open Rheumatology, 2022, , .	2.1	0
24	Single-cell RNA-seq reveals cell typeâ€"specific molecular and genetic associations to lupus. Science, 2022, 376, eabf1970.	12.6	156
25	Predictors of <scp>Thirtyâ€Day</scp> Hospital Readmissions in Systemic Lupus Erythematosus in the <scp>US</scp> : A Nationwide Study. Arthritis Care and Research, 2022, , .	3.4	1
26	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open, 2022, 8, e002187.	3.8	34
27	Dynamics of Methylation of <scp>CpG</scp> Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis and Rheumatology, 2022, 74, 1676-1686.	5.6	5
28	Racial and ethnic differences in COVID-19 outcomes: a call to action. Lancet Rheumatology, The, 2022, 4, e455-e457.	3.9	4
29	Mortality Among Hospitalized Individuals With Systemic Lupus Erythematosus in the US Between 2006 and 2016. Arthritis Care and Research, 2021, 73, 1444-1450.	3.4	17
30	Response to: â€˜Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquineâ€™ by Carbillon et al. Annals of the Rheumatic Diseases, 2021, 80, e55-e55.	0.9	5
31	Response to: â€˜Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosisâ€™ by GyÃ¶rfi et al. Annals of the Rheumatic Diseases, 2021, 80, e88-e88.	0.9	8
32	Association of Race and Ethnicity With COVIDâ€19 Outcomes in Rheumatic Disease: Data From the COVIDâ€19 Global Rheumatology Alliance Physician Registry. Arthritis and Rheumatology, 2021, 73, 374-380.	5.6	66
33	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology, 2021, 60, 353-358.	1.9	32
34	Impact of Limited Health Literacy on Patientâ€Reported Outcomes in Systemic Lupus Erythematosus. Arthritis Care and Research, 2021, 73, 110-119.	3.4	24
35	Major Depression and Adverse Patientâ€Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort. Arthritis Care and Research, 2021, 73, 48-54.	3.4	25
36	Development of a Set of Lupusâ€Specific, Ambulatory Careâ€"Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. Arthritis Care and Research, 2021, 73, 146-157.	3.4	15

#	Article	IF	Citations
37	Race, Ethnicity and Disparities in Rheumatology Educational Materials. Arthritis Care and Research, 2021, , .	3.4	10
38	The racial/ethnic and sociocultural aspects of the pandemic in rheumatology. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101665.	3.3	3
39	Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures. Communications Biology, 2021, 4, 488.	4.4	25
40	Type I interferon, anti-interferon antibodies, and COVID-19. Lancet Rheumatology, The, 2021, 3, e246-e247.	3.9	23
41	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.9	151
42	Inflammatory arthritis in patients with COVID-19. Translational Research, 2021, 232, 49-59.	5.0	19
43	The Development of the Rheumatology Informatics System for Effectiveness Learning Collaborative for Improving Patientâ€Reported Outcome Collection and Patientâ€Centered Communication in Adult Rheumatology. ACR Open Rheumatology, 2021, 3, 690-698.	2.1	5
44	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. Rheumatology International, 2021, 41, 1755-1761.	3.0	12
45	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. JAMA Network Open, 2021, 4, e2119400.	5.9	29
46	Factors Associated With Hospitalization and Death After COVIDâ€19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data. ACR Open Rheumatology, 2021, 3, 796-803.	2.1	5
47	Epidemiology and treatment of BehÃ§etâ€™s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. Arthritis Research and Therapy, 2021, 23, 224.	3.5	10
48	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	3.8	121
49	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	3.9	40
50	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2021, 80, 930-942.	0.9	496
51	Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. Current Opinion in Rheumatology, 2021, 33, 111-116.	4.3	12
52	Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. Journal of Rheumatology, 2021, , jrheum.211000.	2.0	1
53	Shifting knowledge and attitudes about biosimilars among rheumatologists. Rheumatology, 2021, 60, 492-493.	1.9	0
54	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	5.9	86

#	Article	IF	Citations
55	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	3.9	38
56	The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatologyâ€™s Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. JMIR Medical Informatics, 2021, 9, e31186.	2.6	4
57	Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study. Arthritis Care and Research, 2020, 72, 283-291.	3.4	7
58	Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. Arthritis Care and Research, 2020, 72, 622-629.	3.4	77
59	Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Health Care Settings. Arthritis Care and Research, 2020, 72, 888-896.	3.4	7
60	Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 525-533.	3.4	24
61	Increased Risk of Ischemic Stroke in Systemic Sclerosis: A National Cohort Study of US Veterans. Journal of Rheumatology, 2020, 47, 82-88.	2.0	10
62	Reimagining Rheumatology: Big Data and the Future of Clinical Practice and Research. Arthritis Care and Research, 2020, 72, 163-165.	3.4	1
63	Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes. Npj Digital Medicine, 2020, 3, 57.	10.9	38
64	Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Annals of Internal Medicine, 2020, 172, 754-755.	3.9	176
65	COVIDâ€19 in Rheumatic Diseases: A Research Agenda. Arthritis and Rheumatology, 2020, 72, 1596-1599.	5.6	8
66	Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Current Opinion in Rheumatology, 2020, 32, 434-440.	4.3	46
67	Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open, 2020, 6, e001247.	3.8	35
68	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: â€˜Correspondence on â€˜Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryâ€™ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials â€“ a real-world district general hospital experienceâ€™ by K. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-218713.	0.9	11
69	The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology, 2020, 59, 1204-1206.	1.9	34
70	Risk of Neuroinflammatory Adverse Events With Tumor Necrosis Factor Inhibitor Treatment. JAMA Neurology, 2020, 77, 933.	9.0	0
71	Capturing Patientâ€Reported Outcomes During the COVIDâ€19 Pandemic: Development of the COVIDâ€19 Global Rheumatology Alliance Patient Experience Survey. Arthritis Care and Research, 2020, 72, 871-873.	3.4	25
72	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2020, 79, 859-866.	0.9	908

#	Article	IF	Citations
73	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1386-1388.	0.9	67
74	The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nature Reviews Rheumatology, 2020, 16, 293-294.	8.0	85
75	Reweighting to address nonparticipation and missing data bias in a longitudinal electronic health record study. Annals of Epidemiology, 2020, 50, 48-51.e2.	1.9	2
76	RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. Seminars in Arthritis and Rheumatism, 2020, 50, 1542-1548.	3.4	15
77	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis and Rheumatology, 2020, 72, 529-556.	5.6	332
78	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care and Research, 2020, 72, 461-488.	3.4	122
79	Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patientâ€Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. ACR Open Rheumatology, 2020, 2, 53-60.	2.1	32
80	Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States. Arthritis and Rheumatology, 2020, 72, 870-873.	5.6	15
81	Patient and clinician perspectives on a patientâ€facing dashboard that visualizes patient reported outcomes in rheumatoid arthritis. Health Expectations, 2020, 23, 846-859.	2.6	17
82	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatology, The, 2020, 2, e250-e253.	3.9	172
83	Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic. Journal of Rheumatology, 2020, 47, 1712-1720.	2.0	2
84	High Disease Severity Among Asians in a US Multiethnic Cohort of Individuals with Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, , .	3.4	8
85	Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2020, 46, 623-638.	1.9	12
86	Conducting research in a pandemic: The power of social media. European Journal of Rheumatology, 2020, 7, S85-S88.	0.6	10
87	2019 American College of Rheumatology Recommended Patientâ€Reported Functional Status Assessment Measures in Rheumatoid Arthritis. Arthritis Care and Research, 2019, 71, 1531-1539.	3.4	39
88	Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials. JAMA Network Open, 2019, 2, e1914745.	5.9	41
89	A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nature Communications, 2019, 10, 3902.	12.8	39
90	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 348-357.	0.7	4

#	Article	IF	Citations
91	Using Health Information Technology to Support Use of Patient-Reported Outcomes in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, 257-273.	1.9	19
92	Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2019, 49, 267-272.	3.4	29
93	Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Medicine, 2019, 16, e1002800.	8.4	23
94	Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis. JAMA Network Open, 2019, 2, e190606.	5.9	135
95	Quality improvement initiatives in rheumatology: an integrative review of the last 5 years. Current Opinion in Rheumatology, 2019, 31, 98-108.	4.3	6
96	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1004-1006.	0.9	23
97	Automated and flexible identification of complex disease: building a model for systemic lupus erythematosus using noisy labeling. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 61-65.	4.4	37
98	â€œAm I OK?â€•using human centered design to empower rheumatoid arthritis patients through patient reported outcomes. Patient Education and Counseling, 2019, 102, 503-510.	2.2	31
99	Psychometric Evaluation of the National Institutes of Health Patientâ€Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis Care and Research, 2019, 71, 1630-1639.	3.4	22
100	Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Seminars in Arthritis and Rheumatism, 2019, 48, 1087-1092.	3.4	37
101	The Evolving Art and Science of American College of Rheumatology Guidelines. Arthritis and Rheumatology, 2019, 71, 2-4.	5.6	8
102	Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates. Journal of Rheumatology, 2019, 46, 370-375.	2.0	19
103	Does Systemic Lupus Erythematosus Care Provided in a Lupus Clinic Result in Higher Quality of Care Than That Provided in a General Rheumatology Clinic?. Arthritis Care and Research, 2018, 70, 1771-1777.	3.4	25
104	Final adult height of patients with childhood-onset systemic lupus erythematosus: a cross sectional analysis. Pediatric Rheumatology, 2018, 16, 30.	2.1	9
105	Improving Patient Safety in Public Hospitals. Journal of Patient Safety, 2018, Publish Ahead of Print, e773-e790.	1.7	2
106	Relationship Between Poverty and Mortality in Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 1101-1106.	3.4	37
107	Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 467-474.	2.2	21
108	The impact of smoking on disease measures in rheumatoid arthritis: the need for appropriate adjustment of time-varying confounding. Rheumatology International, 2018, 38, 313-314.	3.0	1

#	Article	IF	Citations
109	Further Lessons in Pneumocystis Pneumonia Prophylaxis. JAMA Internal Medicine, 2018, 178, 1565.	5.1	1
110	Accurate Measurement In Californiaâ€™s Safety-Net Health Systems Has Gaps And Barriers. Health Affairs, 2018, 37, 1760-1769.	5.2	6
111	Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. JAMA - Journal of the American Medical Association, 2018, 320, 931.	7.4	27
112	Patient-reported outcome measures for use in clinical trials of SLE: a review. Lupus Science and Medicine, 2018, 5, e000279.	2.7	32
113	Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data. JAMA Internal Medicine, 2018, 178, 1544.	5.1	693
114	Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study. JMIR Medical Informatics, 2018, 6, e31.	2.6	14
115	Validity and Responsiveness of a 10â€Item Patientâ€Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population. Arthritis Care and Research, 2017, 69, 338-346.	3.4	32
116	Medicare Part D Plansâ€™ Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease. JAMA Internal Medicine, 2017, 177, 585.	5.1	25
117	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatology International, 2017, 37, 1249-1255.	3.0	61
118	A Prospective Study of the Impact of Current Poverty, History of Poverty, and Exiting Poverty on Accumulation of Disease Damage in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1612-1622.	5.6	41
119	Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab. Medicine (United States), 2017, 96, e6528.	1.0	12
120	Scleroderma and Pelvic Organ Prolapse: A Multidisciplinary Approach to Patient Care and Surgical Planning. Journal of Gynecologic Surgery, 2017, 33, 198-201.	0.1	3
121	Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. Rheumatology International, 2017, 37, 1611-1618.	3.0	11
122	Relationship Between Process of Care and a Subsequent Increase in Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 927-932.	3.4	32
123	Leveraging the electronic health record to improve quality and safety in rheumatology. Rheumatology International, 2017, 37, 1603-1610.	3.0	17
124	Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic. BMC Health Services Research, 2016, 16, 384.	2.2	7
125	Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study. BMC Health Services Research, 2016, 16, 499.	2.2	14
126	National Lupus Hospitalization Trends Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Pneumonia. PLoS ONE, 2016, 11, e0144918.	2.5	37

#	Article	IF	Citations
127	American College of Rheumatology White Paper on Performance Outcome Measures in Rheumatology. Arthritis Care and Research, 2016, 68, 1390-1401.	3.4	24
128	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. Arthritis Care and Research, 2016, 68, 1579-1590.	3.4	43
129	Rheumatology Informatics System for Effectiveness: A National Informaticsâ€Enabled Registry for Quality Improvement. Arthritis Care and Research, 2016, 68, 1866-1873.	3.4	61
130	Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures. Arthritis Care and Research, 2016, 68, 1402-1409.	3.4	13
131	Challenges and Opportunities in Using Patient-reported Outcomes in Quality Measurement in Rheumatology. Rheumatic Disease Clinics of North America, 2016, 42, 363-375.	1.9	12
132	Factors associated with access to rheumatologists for Medicare patients. Seminars in Arthritis and Rheumatism, 2016, 45, 511-518.	3.4	18
133	Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. PLoS ONE, 2016, 11, e0168369.	2.5	4
134	Influence of Continuing Medical Education on Rheumatologistsâ€™ Performance on National Quality Measures for Rheumatoid Arthritis. Rheumatology and Therapy, 2015, 2, 141-151.	2.3	6
135	Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 143.	3.5	180
136	Efficiency Gains for Rheumatology Consultation Using a Novel Electronic Referral System in a Safetyâ€Net Health Setting. Arthritis Care and Research, 2015, 67, 1158-1163.	3.4	29
137	Use and Spending for Biologic Diseaseâ€Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries. Arthritis Care and Research, 2015, 67, 1210-1218.	3.4	14
138	Using Medicare Data to Understand Health Care Valueâ€”Reply. JAMA Internal Medicine, 2015, 175, 462.	5.1	0
139	Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making. Arthritis Research and Therapy, 2015, 17, 367.	3.5	13
140	Coverage for Highâ€Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. Arthritis and Rheumatology, 2015, 67, 1474-1480.	5.6	50
141	Interactions Between Patients, Providers, and Health Systems and Technical Quality of Care. Arthritis Care and Research, 2015, 67, 417-424.	3.4	16
142	Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. Journal of Rheumatology, 2015, 42, 1616-1623.	2.0	23
143	Receipt of Glucocorticoid Monotherapy Among Medicare Beneficiaries With Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 1447-1455.	3.4	19
144	Quality of Care for Incident Lupus Nephritis Among Medicaid Beneficiaries in the United States. Arthritis Care and Research, 2014, 66, 617-624.	3.4	44

#	Article	IF	Citations
145	Using Medicare Data to Understand Low-Value Health Care. JAMA Internal Medicine, 2014, 174, 1702.	5.1	20
146	Thirtyâ€Day Hospital Readmissions in Systemic Lupus Erythematosus: Predictors and Hospitalâ€•and Stateâ€Level Variation. Arthritis and Rheumatology, 2014, 66, 2828-2836.	5.6	54
147	Quality of care in systemic lupus erythematosus: the association between process and outcome measures in the Lupus Outcomes Study. BMJ Quality and Safety, 2014, 23, 659-666.	3.7	37
148	Post-marketing Experiences with Belimumab in the Treatment of SLE Patients. Rheumatic Disease Clinics of North America, 2014, 40, 507-517.	1.9	21
149	Choosing wisely: The American College of Rheumatology's top 5 list of things physicians and patients should question. Arthritis Care and Research, 2013, 65, 329-339.	3.4	89
150	Underestimation of the Reliability of Codes for Rheumatoid Arthritis Within Administrative Data: Comment on the Article by Ng et al. Arthritis Care and Research, 2013, 65, 835-836.	3.4	3
151	Healthcare quality in systemic lupus erythematosus: using Donabedianâ€™s conceptual framework to understand what we know. International Journal of Clinical Rheumatology, 2012, 7, 95-107.	0.3	16
152	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care and Research, 2012, 64, 797-808.	3.4	1,119
153	Quality of Care in Systemic Lupus Erythematosus: Application of Quality Measures to Understand Gaps in Care. Journal of General Internal Medicine, 2012, 27, 1326-1333.	2.6	41
154	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care and Research, 2012, 64, 640-647.	3.4	566
155	Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality?. Arthritis Care and Research, 2011, 63, 358-365.	3.4	76
156	Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators. Arthritis Care and Research, 2011, 63, 17-30.	3.4	17
157	Defining quality of care in rheumatology: The American College of Rheumatology white paper on quality measurement. Arthritis Care and Research, 2011, 63, 2-9.	3.4	37
158	Cardiovascular and diseaseâ€•related predictors of depression in systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 542-549.	3.4	39
159	Brief index of lupus damage: A patientâ€•reported measure of damage in systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 1170-1177.	3.4	86
160	Healthâ€•related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosusâ€Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (Lâ€QoL). Arthritis Care and Research, 2011, 63, S413-9.	3.4	43
161	Quality measurement and improvement in rheumatology: Rheumatoid arthritis as a case study. Arthritis and Rheumatism, 2011, 63, 3649-3660.	6.7	33
162	Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans. JAMA - Journal of the American Medical Association, 2011, 305, 480.	7.4	120

#	Article	IF	Citations
163	Osteoporosis and Cardiovascular Disease Care in Systemic Lupus Erythematosus According to New Quality Indicators. Seminars in Arthritis and Rheumatism, 2010, 40, 193-200.	3.4	29
164	Hydroxychloroquine treatment in a communityâ€based cohort of patients with systemic lupus erythematosus. Arthritis Care and Research, 2010, 62, 386-392.	3.4	34
165	Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care and Research, 2010, 62, 993-1001.	3.4	42
166	Preventing Hepatitis B reactivation in immunosuppressed patients: Is it time to revisit the guidelines?. Arthritis Care and Research, 2010, 62, 585-589.	3.4	16
167	Health-Related Quality of Life and Employment Among Persons with Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2010, 36, 15-32.	1.9	29
168	Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Research and Therapy, 2010, 12, R84.	3.5	59
169	Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 240-246.	6.7	163
170	A quality indicator set for systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 370-377.	6.7	122
171	Validation of the systemic lupus erythematosus activity questionnaire in a large observational cohort. Arthritis and Rheumatism, 2008, 59, 136-143.	6.7	102
172	Quality of care in the rheumatic diseases: current status and future directions. Current Opinion in Rheumatology, 2008, 20, 159-166.	4.3	29
173	The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. Journal of Rheumatology, 2008, 35, 1782-8.	2.0	60
174	Association of socioeconomic and demographic factors with utilization of rheumatology subspecialty care in systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 57, 593-600.	6.7	59
175	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. Global Rheumatology, 0, , .	0.0	10